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Abstract
Introduction: Emerging epidemiological evidence suggests that proton pump inhibitor (PPI) acid-suppression therapy is
associated with an increased risk of Clostridium difficile infection (CDI).
Methods: Ovid MEDLINE, EMBASE, ISI Web of Science, and Scopus were searched from 1990 to January 2012 for analytical
studies that reported an adjusted effect estimate of the association between PPI use and CDI. We performed random-effect
meta-analyses. We used the GRADE framework to interpret the findings.
Results: We identified 47 eligible citations (37 case-control and 14 cohort studies) with corresponding 51 effect estimates.
The pooled OR was 1.65, 95% CI (1.47, 1.85), I2 = 89.9%, with evidence of publication bias suggested by a contour funnel
plot. A novel regression based method was used to adjust for publication bias and resulted in an adjusted pooled OR of 1.51
(95% CI, 1.26–1.83). In a speculative analysis that assumes that this association is based on causality, and based on published
baseline CDI incidence, the risk of CDI would be very low in the general population taking PPIs with an estimated NNH of
3925 at 1 year.
Conclusions: In this rigorously conducted systemic review and meta-analysis, we found very low quality evidence (GRADE
class) for an association between PPI use and CDI that does not support a cause-effect relationship.
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Introduction
Proton pump inhibitors (PPIs) are one of the most prescribed
groups of drugs globally [1]. PPIs are effective for the treatment of
all acid-related disorders. They are also indicated ICU patients
with coagulopathy, patients on mechanical ventilation, and
patients with history of peptic ulcer disease, (particularly those
on NSAID or antiplatelet therapy) [2].
The use of PPIs has increased dramatically [1] despite concerns
that PPIs are overprescribed both in primary care [3] and in
hospitals, both in the in-patient setting [4–7] and on discharge [8].
Moreover, concerns have been raised about the potential long-
term effects of these drugs. PPIs have been associated with
significant interaction with other drugs [9,10] and fractures [11],
interstitial nephritis [12], pneumonia [13] and enteric infections
[14,15], namely Clostridium difficile infection (CDI).
CDI has recently emerged as a major public health problem
with current estimates suggesting a point prevalence of 13.1/1000
in-patient population [16]. Studies have reported increases in both
incidence and mortality of CDI [17–20]. The increase in incidence
of CDI has been attributed to an aging population, increase in use
of antibiotics and acid suppressive drugs. PPIs are postulated to
increase the proliferation of spores and change the acidic milieu of
the stomach that permits spores to survive intraluminally.
The role of gastric acid suppression therapy has gained much
interest recently as a risk factor for CDI. Four recently published
meta-analyses have suggested an association between gastric acid
suppression therapy with proton pump inhibitors (PPI) and CDI
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[15,21,22,23]. The United States Food and Drug Administration
(FDA) recently warned the public about a possible association
between CDI and PPI use [19]. Nevertheless, these reviews had
important limitations such as missing a large number of published
studies [15,19,22,23], using only unadjusted data from observa-
tional studies [15,22,23], not exploring heterogeneity and the
effect of publication bias and over-interpreting the findings. We,
therefore, performed a systematic review and meta-analysis that
addressed the role of PPIs in CDI. We used the MOOSE [24] and
PRISMA guidelines [25] for reporting systematic reviews. We
include new studies published after the previous meta-analyses and
added unique approaches to adjust for publication bias as well as
explore the potential effect of unknown confounders. We use the
Grades of Recommendation, Assessment, Development and
Evaluation (GRADE) framework [26] to interpret our findings.
Methods
Study Search Strategy
The search strategy and subsequent literature searches were
performed by a medical reference librarian (PJE) with 38 years of
experience. The initial strategy was developed in Ovid MEDLINE
(1990 through January 2012), using MeSH (Medical Subject
Headings) controlled vocabulary, and then modified for Ovid
EMBASE (1990 through January 2012). The search was intended
to capture all acid suppression studies. Primary terms were:
enterocolitis, pseudomembranous/AND the therapeutic agents of
interest: explode omeprazole, explode proton pump inhibitors,
anti-ulcer agents, and explode histamine H2 antagonists (Explode
allows including all of the specific drugs, without having to use all
of the various terms, synonyms, brands and generic names.)
Articles were limited to randomized controlled trials, cohort
studies, and/or case-control studies. The same process was used
with Ovid EMBASE with alterations as necessary to accommodate
EMBASE’s more granular subject headings. ISI Web of Science
and Elsevier Scopus use textwords: (difficile OR pseudomembra-
nous OR pseudo-membranous) AND (omeprazole OR ‘‘proton
pump’’ OR ranitidine OR h2 OR h-2 OR ‘‘acid suppression’’ OR
antacid*)) AND (random* OR trial* OR blind* OR cohort* OR
controlled OR prospective).
There was no restriction on language. All results were downloaded
into EndNote 7.0 (Thompson ISI Research soft, Philadelphia,
Pennsylvania), a bibliographic database manager, and duplicate
citations were identified and removed. Two authors (A.B.A. and
F.A.) independently assessed the eligibility of identified studies.
Study Selection
To be included, a study had to: (1) be an analytical study; and (2)
have examined the association between PPI use and incidence of CDI.
Data Collection
A data collection form was developed and used to retrieve
information on relevant features and results of pertinent studies.
Two reviewers (A.B.A. and F.A.) independently extracted and
recorded data on a predefined checklist. Disagreements among
reviewers were discussed with two other reviewers (I.M.T. and
M.A.), and agreement was reached by consensus. Data included
the following: study characteristics (i.e., country and year of study),
characteristics of the study, PPI intake definition and ascertain-
ment, and outcome. We also collected adjusted effect estimates
and 95% confidence intervals (CI) based on the multivariable
regression model used in each study, and the list of variables
considered for inclusion in the multivariate analysis.
We used the Newcastle-Ottawa Quality Assessment Scale for cohort
and case-control studies [27] which is intended to rate selection bias,
comparability of the exposed and unexposed groups of each cohort,
outcome assessment, and attrition bias. Two reviewers (A.B.A. and
F.A.) independently assessed the methodological quality of selected
studies using the Newcastle-Ottawa Quality Assessment Scale for
cohort and case-control studies. Disagreement among reviewers was
discussed with 2 other reviewers (I.M.T. and M.A.), and agreement
was reached by consensus.
We used the GRADE framework to interpret our findings. The
Cochrane Collaboration has adopted the principles of the
GRADE system [28] for evaluating the quality of evidence for
outcomes reported in systematic reviews.
For purposes of systematic reviews, the GRADE approach
defines the quality of a body of evidence as the extent to which one
can be confident that an estimate of effect or association is close to
the quantity of specific interest. Quality of a body of evidence
involves consideration of within-study risk of bias (methodological
quality), directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias.
Statistical Analyses
Meta-analyses. The primary effect measures used in the
meta-analysis were Odds Ratios (OR) (46 observations), and
Hazard Ratios (HR) (5 observations) which were assumed to
reasonably estimate the same association between CDI and PPIs
because of low CDI incidence and are pooled together. Adjusted
effect estimates were primarily used for this analysis. Unadjusted
effect estimates were used as alternatives if studies did not observe
an association on univariate comparison and did not therefore
pursue adjustment or did not report adjusted estimates. We
performed meta-analyses for all studies together and separately for
different subgroups such as case-control studies and cohort studies.
Effect estimates from all included studies were pooled in a meta-
analysis using the DerSimonian and Laird random effects model [29].
Exploring heterogeneity. Homogeneity among studies was
estimated by calculation of the variation across studies attributable
to heterogeneity rather than chance (I2). The influence of a range
of a-priori selected study-level and aggregated individual-level
parameters on the observed effect estimate was investigated by
means of meta-regressions. In these analyses, the log odds ratio
from each study was regressed on the potential confounders in
univariate and multivariate weighted linear regressions, weighted
according to the inverse standard error and the residual between-
study variance. Nine potential confounders were considered. Six
variables were categorical: design of the study (case-control vs.
cohort), country of publication, setting (single center vs. multicen-
ter), method of ascertainment of antibiotic use, method of effect
measure (OR vs. RR/HR) and effect estimate (adjusted vs.
unadjusted). Three continuous variables were: the impact factor of
the journal where the study was published, number of variables the
effect measure was adjusted for and proportion of cases that were
exposed to antibiotics.
Publication bias. The possible influence of publication bias
was graphically assessed with the novel method of contour-
enhanced funnel plot [30] where log-transformed odds ratios were
plotted against standard errors. This method examines whether
any funnel plot asymmetry is likely to be due to publication bias
compared with other underlying causes of funnel plot asymmetry.
The contours help to indicate whether areas of the plot, where
studies are perceived to be missing, are where studies would have
statistically significant effect sizes or not and thus decrease or
increase the evidence that the asymmetry is due to publication
bias. The presence of funnel plot asymmetry was also assessed
Proton Pump Inhibitors and C. difficile Infection
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e50836
using Egger’s test [31]. To adjust for the impact of publication bias
on the pooled effect estimate, we used a novel regression based
adjustment method recently suggested by Moreno et al [32]. An
adjusted pooled effect estimate for an ideal study of a very large
size (i.e. with zero standard error) is obtained from the fitted
weighted linear regression equation, plotted with a regression line
on the contour enhanced funnel plot. This method of regression is
a modified version of conventional Egger’s regression test for
publication bias where the log of effect estimate is regressed by its
variance rather than the standard error and weights are assigned
according to the inverse of the variance. This model has been
shown to consistently outperform the conventional trim and fill
method [32].
Residual confounding. Finally, the possible influence of
unknown confounders (residual confounding) was investigated
with a rule-out approach described by Schneeweiss [33]. This
approach stipulates the influence of a hypothetical confounder and
determines what characteristics this confounder must have to fully
account for the observed association between use of PPIs and
occurrence of CDI. The hypothetical confounder is characterized
by its association to PPIs use (OREC, odds ratio of exposure to the
confounder) and its association to the outcome (RRCO, relative
risk of outcome in individuals exposed to the confounder vs. non-
exposed). For this analysis, the absolute risk in the pooled non-
exposed group was used for conversion of odds ratio to relative risk
using the method described by Zhang and Yu [34]. Separate
analyses were performed to demonstrate what levels of OREC and
RRCO would be required to fully explain the observed association
between PPIs and CDI for different hypothetical prevalence of the
unknown confounder (i.e. PC= 0.2, PC= 0.5) before and after
adjustment for publication bias as described above.
In all analyses, results associated with p-values ,0.05 (two-sided
test) were considered statistically significant. All statistical analyses
were performed using Stata version12 statistical software (Stata
Corp, College Station, Texas).
Results
Yield of Search Strategy and Eligible Studies
The search strategy yielded 287 publications of which 242 were
not eligible for inclusion based on title/abstract review. Reference
lists of all eligible articles were systematically searched and 7
additional studies were identified that were not captured by our
search strategy. A total of 47 citations, 4 of which reported data on
4 different populations, that examined the association between PPI
therapy and CDI were eligible for this review. Figure 1
summarizes the study selection process and is presented in the
appendix.
Figure 1. Flow diagram of eligible studies.
doi:10.1371/journal.pone.0050836.g001
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Characteristics of the Included Studies
Table 1 summarizes characteristics of the included studies.
Studies were conducted in Asia, Europe, North America (Canada
and USA). One citation reported both a case-control and cohort
designs on 2 different patient populations [35]. Three citations
[36–38] reported two different case control analyses per each
citation. Forty analyses were single-centre, nine were multi-centre,
and two from a general practice research database (GPRD). Thirty
seven analyses were of case-control design and 14 were of cohort
design. Among these, 8 exclusively addressed community-acquired
CDI, 37 hospital-acquired and 6 both hospital- and community-
acquired CDI. Table S1 and S2 summarizes the CDI case
ascertainment and control or non-exposed group selection method
for all studies.
Quality Assessment of Included Studies
Quality assessment of all included studies was done using the
validated Newcastle-Ottawa Quality Assessment Scale [27] for
cohort and case control studies (Table S3 and Table S4). Most
studies were of good quality with no evidence of selection bias, and
with good comparability of the exposed and unexposed groups of
each cohort, and outcome assessment. Fifty-one individual effect
estimates from 47 eligible citations were extracted. We identified 2
outliers and excluded them from the final analyses as per the
Cochrane Handbook for Systematic Reviews [39]. The 2 outliers
were: Bajaj et al [40] because of a high OR=37.6, and Wilcox
et al [41] because of large SE (SE log OR=3.59). Final
interpretation was based on analyses of the 51 observations.
Meta-analysis
Association between PPI and CDI. Fifty one individual
effect estimates from 47 eligible studies were extracted. Figure 2
shows the results of the pooled estimates for the 51 observations.
The pooled OR for the 51 observations was 1.65, 95% CI (1.47,
1.85), I2 = 89.9%. Table 2 summarizes the pooled estimates and
associated heterogeneity for different subgroups. All estimates
supported an association between PPI therapy and CDI.
Exploring heterogeneity. The influence of a range of a-
priori selected study-level and aggregated individual-level param-
eters on the observed effect estimate was investigated by means of
meta-regressions. Table S5 summarizes the meta-regression
analyses for all 51 results and is presented in the appendix. We
observed that studies that used interviews to ascertain PPI
exposure had on average lower effect estimates that studies that
used medical records 1.17 (0.91, 1.51) vs. 1.89 (1.45, 2.45), p for
interaction = 0.05 (Table 2). We also observed that studies that
used adjusted effect estimates [1.76 (95% CI, 1.54, 2.00)] had
higher pooled estimates than those that used unadjusted effect
estimates [1.27 (95% CI, 0.93, 1.72)], p = 0.07.
Publication bias. Figure 3 displays a contour-enhanced
funnel plot with the corresponding fixed (FE) and random effect
(RE) meta-analyses pooled estimates providing a weighted average
of effect size across studies of 1.02 (95% CI, 1.01–1.03) and 1.65
(95% CI, 1.47–1.85) respectively. There was visual evidence of
funnel asymmetry and Egger’s test for publication bias, P = 0.001.
Hence, a novel regression based method was used to adjust for
publication bias.
The fitted regression line plotted in Figure 3 corresponds to the
regression-based adjustment method. The adjusted estimate is
obtained by extrapolating the line with a standard error of 0 (at the
top of the funnel plot). This produced an adjusted average effect
estimate (RE model) of 1.51 (95% CI, 1.26–1.83).
Residual confounding. The results of the residual confound-
ing analysis are presented in Figure 4. Panel A refers to a
confounder with a prevalence of 0.20 and at this prevalence level,
even a strong confounder causing a 2.5-fold increased risk of CDI
would have to be imbalanced between acid-suppression users and
non-users (OREC=3.8) to fully account for the observed adjusted
RR of 1.32 (adjusted for publication bias). For a very common
confounder with a prevalence of 0.50 (Panel B) and causing a 2.5-
fold increased risk of CDI, it would have to be distinctly
imbalanced between acid-suppression users and non-users
(OREC=5.38) to fully account for the observed adjusted RR of
1.32.
Number Needed to Harm
The number needed to harm (NNH) was estimated by using the
pooled OR from the meta-analysis [42]. This analysis is only
speculative as it assumes there is a cause-effect relationship
between PPI and CDI. A recent large prospective hospital cohort
[43] reported the incidence of CDI at 14 days after hospital
admission in patients receiving antibiotics or not: which was 42/
1,000 and 5.4/1000, respectively. Based on these reported baseline
risks, the number needed to harm (NNH) was 50, 95% CI (31, 97)
and 367, 95% CI (226, 718), respectively. For the general
population, the NNH at 1 year was 3925, 95% CI (2412, 7698) at
1 year, based on a baseline incidence of CDI of 48/100,000
person-years [39].
Discussion
Findings
In this rigorously conducted systemic review and meta-analysis,
we observed a weak association between PPI use and risk of CDI.
This association was further weakened by the presence of
significant heterogeneity. Although we adjusted for publication
bias and ruled out a strong effect of an unmeasured confounder,
the cumulative evidence provided by this systematic review
constitutes only very low quality evidence (as per GRADE
framework) in favor of this association. Factors that negatively
influence the quality of the evidence include the observational
design, inconsistency of results, and evidence of publication bias.
Moreover, even if we assume that the pooled effect estimate is valid, the
absolute risk of CDI would be very low in the general population
with an estimated NNH of 3925 at 1 year. In contrast, the risk
would behighest in hospitalized patients receiving antibiotics with
an estimated NNH of 50 at 2 weeks.
Comparison to Other Studies
Several systematic reviews [15,21–23,44,45] examining this
association have been published previously; however, our review is
the most comprehensive and is unique in its analytical approach
and interpretation and thus adds substantially to the cumulative
evidence. Table 3 summarizes the differences between our
systematic and those recently published. First, our review
identified the largest number of studies published to date. For
example, our review has 36% more studies than the largest meta-
analysis by Kowk et al [21] and 90% more studies that the recent
FDA review published in February 2012. Second, our meta-
analysis included adjusted effect estimates of the association
between PPI and CDI. Third, we used meta-regression to explore
sources of heterogeneity. None of the published analyses used this
method. Fourth, we examined the effect of publication bias using a
novel approach of contour-enhanced funnel plot [46]. The largest
and most recent analysis by Kowk et al. [21] did not examine the
effect of publication bias. Fifth, we used a novel regression-based
method to adjust the pooled estimate for publication bias and we
Proton Pump Inhibitors and C. difficile Infection
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examined the potential effect of a residual confounding on the
observed association using the rule-out approach.
Finally, we interpret the results in the context of observed
limitations and therefore, draw more careful conclusions. Contrary
to other reviews and FDA alert, we conclude that current
cumulative data constitutes very low quality evidence. Our results
are helpful for guidelines writing committees and policy makers
that use the GRADE framework when formulating recommenda-
tions for use of PPI for different clinical indications.
Biologic Plausibility
The mechanism by which PPI therapy contributes to an
increased risk of CDI is unclear, because gastric acid does not kill
Figure 2. Forest Plot of the Meta analyses of The Association Between CDI and Proton Pump Inhibitors Based on 51 Observations.
doi:10.1371/journal.pone.0050836.g002
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gastric C. difficile spores. This further makes a cause-effect
relationship a less likely explanation for the observed association.
It has been proposed that the vegetative form of C. difficile,
which is killed by acid, plays a role in pathogenesis. Vegetative
forms survive on surfaces and could be ingested by patients [47].
Survival of these acid-sensitive vegetative forms in the stomach
could be facilitated by 2 main factors: (1) suppression of gastric
acid production by acid-suppressive medications; and (2) presence
of bile salts in gastric contents of patients on acid-suppressive
therapy. Bile salts, which are mainly found in the small intestine,
are present in gastric contents, particularly among patients with
gastro-esophageal reflux disease (GERD). Moreover, PPI use can
delay gastric emptying and predispose to bacterial overgrowth
with associated high intragastric bile salts which could trigger
spore germination in the stomach [48–50].
However, a recent in vitro experiment has challenged these
postulated biological mechanisms for the observed association. In
this experiment, aspirate of gastric contents from hospitalized
patients with nasogastric tubes were collected. It concluded that C.
difficile spores were not killed in acidic gastric content and did not
Table 2. Influence of study type, country, weather effect estimate adjusted or not and PPI ascertainment method on the pooled
effect estimate and its associated heterogeneity.
Group Pooled Effect Estimate 95% CI I2% Number of Observations
All citations 1.65 (1.47, 1.85) 89.9 51
Case-control citations 1.70 (1.42, 2.03) 88.7 37
Cohort citations 1.64 (1.30, 2.08) 87.8 14
Asia 3.26(1.91, 5.58) 0.0 3
Canada 1.22 (1.09, 1.37) 82.1 14
Europe 1.90 (1.35, 2.66) 75.5 10
USA 1.70 (1.41, 2.04) 73.3 24
Studies reported adjusted effect estimates* 1.78 (1.56, 2.02) 92.2 37
Studies reported unadjusted effect estimates* 1.27 (0.93, 1.71) 59.4 14
PPI ascertainment method (Chart){ 1.89 (1.45, 2.45) 93.6 20
PPI ascertainment method (Interview){ 1.17 (0.91, 1.51) 79.0 8
doi:10.1371/journal.pone.0050836.t002
Figure 3. Contour enhanced funnel plot of the association between the effect-estimates and its standard errors: * Contour enhanced
funnel plots with implementation of regression adjustment model (adjusted effect at top where SE is 0).* The contour lines differentiate the
significance and non-significance regions in the plot at 1%, 5% and 10% significance levels. *Vertical lines show average effect-estimates from
random effect (red), and fixed effect models (blue). *A regression line (black) is added for regression based adjustment (With adjusted effect estimate
and 95% CI at top where SE is 0). Abbreviations: FEMA: Fixed effect meta-analysis, REMA: Random effect meta-analysis, Reg: Regression line.
doi:10.1371/journal.pone.0050836.g003
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Figure 4. Influence of a hypothetical dichotomous confounder present in 20% (panel A) and 50% (panel B) of the study population,
unaccounted for in the adjustments already performed in the individual studies. The graphs indicate what combinations of OREC and RR
that would be necessary for the confounder to fully account for the observed association between proton pump inhibitor (PPI) use and CDAD after
adjustment for publication bias. Abbreviations: OREC, odds ratio of exposure to the confounder in PPI non-users vs. acid-suppression users; RRCD,
relative risk of CDAD in individuals exposed to the confounder vs. non-exposed.
doi:10.1371/journal.pone.0050836.g004
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germinate in gastric contents of hospitalized patients on PPI.
Germination occurred with the addition of taurocholic acid [51].
Limitations
There are limitations to our work. First, observational studies
are subject to inherent limitations in the study design leading to
unmeasured differences in the study population and unmeasured
confounders despite all possible adjustments. PPIs use may be a
surrogate of comorbidities and thus, the observed association may
have been affected by selective overuse of PPIs in high risk groups.
For example, the potential interaction between PPIs and
Clopidogrel found in observational studies was refuted in
randomized controlled trials [52]. Second, the use of PPIs was
based on electronic and prescription records, rather than by actual
use by the patient. Third, there is presence of publication bias, and
substantial amount of heterogeneity in the included studies. There
are many patient level parameters which may have led to
substantial heterogeneity. Nevertheless, investigating these vari-
ables is only possible with individual patient data meta-analysis.
Fourth, all statistical methods used to assess for publication bias or
residual confounding are subject to certain assumptions and have
inherent limitations. For example, funnel plot asymmetry can be
due to between studies heterogeneity rather than publication bias
[31].
Given these limitations, focus on hand hygiene as one of the
cornerstones of prevention of nosocomial transmission of C. difficile
is warranted. Several studies have documented the reduction of
rates of hospital acquired infection by improvement in the
compliance with hand washing by healthcare workers between
episodes of contact with patients [53].
Conclusions
In this rigorously conducted systemic review and meta-analysis,
we found very low quality evidence in support of an association
between PPI use and risk of CDI. This association was weakened
by the presence of significant heterogeneity and publication bias.
Our findings are re-assuring that PPIs use in the general
population does not pose a significant CDI risk. On the other
hand, our findings warrant judicious and evidence-based use of
PPI in patients at high risk for CDI.
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Figure S1 Forest plot of the meta-analysis of the
proportion of Clostridium difficile cases that were
exposed to antibiotics.
(DOCX)
Author Contributions
Analyzed the data: IMT AJS MR ABA MAA MAG. Wrote the paper:
IMT MR ARK ABA MAA MAG MA. Study concept and design: IMT
AJS MR PJE. Data abstraction: ABA FAA MA AA TI MAG. Quality
assessment: FAA ABA MAG. Revision of the manuscript: IMT AJS MR
ABA FAA MAA AA TI MAG ARK LMB.
References
1. IMS Health (2005) Leading 20 therapeutic classes by U.S. sales, Available: http:
//www.imshealth.com/ims/portal/front/articleC/0,2777,6599_73915261_
77140565,00.html. Accessed 2006 June.
2. Yachimski PS, Farrell EA, Hunt DP, Reid AE (2010) Proton Pump Inhibitors for
Prophylaxis of Nosocomial Upper Gastrointestinal Tract BleedingEffect of
Standardized Guidelines on Prescribing Practice. Arch Intern Med. 2010;170(9):
779–783.
3. Batuwitage BT, Kingham JGC, Morgan NE, Bartlett RL (2007) Inappropriate
prescribing of proton pump inhibitors in primary care. Postgrad Med J 83: 66–
68.
4. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, et al. (2010) Potentially
inappropriate prescribing and cost outcomes for older people: a national
population study. Br J Clin Pharmacol 69(5): 543–552.
5. Mat Saad AZ, Collins N, Lobo MM, O’Connor HJ (2005) Proton pump
inhibitors: a survey of prescribing in an Irish general hospital. Int J Clin Pract 59:
31–34.
6. Niklasson A, Bajor A, Bergendal L, Simren M, Strid H, et al. (2003) Overuse of
acid suppressive therapy in hospitalized patients with pulmonary diseases. Respir
Med 97: 1143–1150.
7. Scagliarini R, Magnani E, Pratico A, Bocchini R, Sambo P, et al. (2005)
Inadequate use of acid-suppressive therapy in hospitalized patients and its
implications for general practice. Dig Dis Sci 50: 2307–2311.
8. Ahrens D, Chenot JF, Behrens G, Grimmsmann T, Kochen MM (2010)
Appropriateness of treatment recommendations for PPI in hospital discharge
letters. Eur J Clin Pharmacol 66(12): 1265–1271.
9. US Food and Drug Administration (2009) Information for healthcare
professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix)
to alert healthcare professionals about a drug interaction with omeprazole
(marketed as Prilosec and Prilosec OTC). U.S. Department of Health and
Human Services, 11/17/2009. http: //www.fda.gov/Drugs/Drug Safety/
Postmarket Drug Safety Information for Patients and Providers/Drug Safety
Information for Heath,care Professionals/ucm190787.htm. Accessed 9/23/
2010.
10. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, et al. (2011) Proton
pump inhibitor use and risk of adverse cardiovascular events in aspirin treated
patients with first time myocardial infarction: nation-wide propensity score-
matched study. BMJ 342: d2690.
11. Eom CS, Park SM, Myung SK, Yun JM, Ahn JS (2011) Use of acid suppressive
drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam
Med 9(3): 257–267.
12. Sierra F, Suarez M, Rey M, Vela MF (2007) Systematic review: proton pump
inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 26:
545–553.
13. Johnstone J, Nerenberg K, Loeb M (2010) Meta-analysis: proton pump inhibitor
use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther
31(11): 1165–1177.
14. Dial MS. (2009) Proton pump inhibitor use and enteric infections.
Am J Gastroenterol (suppl 2): S10–S16.
15. Leonard J, Marshall JK, Moayyedi P (2007) Systematic review of the risk of
enteric infection in patients taking acid suppression. Am J Gastroenterol 102:
2047–2056.
16. Jarvis WR, Schlosser J, Jarvis AA, Chinn RY (2009) National point prevalence of
Clostridium difficile in US health care facility inpatients, 2008. Am J Infect
Control 37: 263–270.
17. Archibald LK, Banerjee SN, Jarvis WR (2004) Secular trends in hospital-
acquired Clostridium difficile disease in the United States. J Infect Dis 189:
1585–1589.
18. McDonald LC, Owings M, Jernigan JB (2006) Clostridium difficile infection in
patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis
12: 409–415.
19. Elixhauser A, Jhung M (2008) Clostridium difficile-associated disease in US
hospitals, 1993–2005. HCUP statistical brief No. 50, April 2008. US Agency for
Healthcare Research and Quality, Rockville, MD. Available at: http: //www.
hcup-us.ahrq.gov/reports/statbriefs.sb50.pdf. Accessed February 16, 2009.
20. Redelings MD, Sorvillo F, Mascola L (2007) Increase in Clostridium difficile-
related mortality rates, United States, 1999e2004. Emerg Infect Dis 13(9): 1417–
1419.
21. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, et al. (2012) Risk of
Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-
Analysis. Am J Gastroenterol 107(7): 1011–1019.
22. Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, et al. (2012) Association
between proton pump inhibitor therapy and Clostridium difficile infection in a
meta-analysis. Clin Gastroenterol Hepatol 10(3): 225–233.
23. Bavishi C, Dupont HL (2011) Systematic review: the use of proton pump
inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol
Ther 34(11–12): 1269–1281.
24. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-
analysis of Observational Studies in Epidemiology: A Proposal for Reporting.
JAMA 283: 2008–2012.
25. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The
PRISMA statement for reporting systematic reviews and meta-analyses of studies
that evaluate healthcare interventions: explanation and elaboration. BMJ
2009;339: b2700.
26. Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, et al. (2008) Rating
quality of evidence and strength of recommendations GRADE: an emerging
consensus on rating quality of evidence and strength of recommendations. BMJ
336: 924–926.
27. Wells G, Shea B, O’Connell D, Peterson J, Welch V et al. The Newcastle-
Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta-
analysis. Ottawa, Ontario: The Ottawa Health Research Institute. Available:
http: //www.ohri.ca/programs/clinicalepidemiology/nosgen.doc. Accessed on
2011 September 13.
28. Higgins JPT, Altman DG (2008) Chapter 8: Assessing risk of bias in included
studies. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic
Reviews of Interventions Version 5.0.1 [updated September 2008] The
Cochrane Collaboration, 2008. Available: www.cochrane-handbook.org. Ac-
cessed 2010 December 15.
29. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin
Trials 7(3): 177–188.
30. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2008) Contour-
enhanced meta-analysis funnel plots help distinguishing publications bias from
other causes of asymmetry. J Clin Epidemiol 61: 991–996.
31. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis
detected by a simple, graphical test. BMJ 315: 629–634.
32. Moreno SG, Sutton AJ, Ades AE, Stanley TD, Abrams KR, et al. (2009)
Assessment of regression-based methods to adjust for publication bias through a
comprehensive simulation study. BMC Med Res Methodol 9: 2.
33. Schneeweiss S (2006) Sensitivity analysis and external adjustment for
unmeasured confounders in epidemiologic database studies of therapeutics.
Pharmacoepidemiol Drug Saf 15: 291–303.
34. Zhang J, Yu KF (1998) What’s a relative risk? A method of correcting the odds
ratio in cohort studies of common outcomes. JAMA 280: 1690–1691.
35. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D (2004) Risk of
Clostridium difficile diarrhea among hospital inpatients prescribed proton pump
inhibitors: cohort and case-control studies. CMAJ 171(1): 33–38.
36. Kutty PK, Woods CW, Sena AC (2010) Risk Factors for and Estimated
Incidence of Community-associated Clostridium difficile Infection, North Carolina,
USA. Emerg Infect Dis 16(2): 197–204.
37. Jayatilaka S, Shakor R, Eddi R, Bakaj G, Baddoura WJ, et al. (2007) Clostridium
difficile Infection in an Urban Medical Centre: Five-year Analysis of Infection
Rates among Adults admissions and Association with the Use of Protein Pump
Inhibitors. Ann Clin Lab Sci 37(3): 241–247.
38. Linney S, Fernandes T, Einarson T, Sengar A, Walker JH, et al. (2010)
Association Between Use of Proton Pump Inhibitors and a Clostridium difficile–
Associated Disease Outbreak: Case–Control Study. Can J Hosp Pharm 63(1):
31–37.
39. http: //www.cochrane-net.org/openlearning/html/mod14-2.htm.
40. Bajaj JS, Ananthakrishnan AN, Hafeezullah M, Zadvornova Y, Dye A, et al.
(2010) Clostridium difficile is Associated With Poor Outcomes in Patients With
Cirrhosis: A National and Tertiary Center Perspective. Am J Gastroenterol 105:
106–113.
41. Wilcox CM, Martin T, Phadnis M, Mohnen J, Worthington J, et al. (2008)
Absence of gastrointestinal infections in a cohort of patients with Zollinger-
Ellison syndrome and other acid hypersecretors receiving long-term acid
suppression with lansoprazole. BMC Gastroenterol 8: 18.
42. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN (2006) Proton pump
inhibitors and hospitalization for Clostridium difficile–associated disease: a
population-based study. Clin Infect Dis 43(10): 1272–1276.
43. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, et al. (2010)
Iatrogenic Gastric Acid Suppression and the Risk of Nosocomial Clostridium
difficile Infection. Arch Intern Med 170(9): 784–790.
44. Available: http: //www.fda.gov/Drugs/DrugSafety/ucm290510.htm.Accessed
2012 February 14.
45. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN (2012) Clostridium difficile-
Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis.
Am J Gastroenterol 107(7): 1001–1010.
Proton Pump Inhibitors and C. difficile Infection
PLOS ONE | www.plosone.org 11 December 2012 | Volume 7 | Issue 12 | e50836
46. Moreno SG, Sutton AJ, Turner EH, Abrams KR, Cooper NJ, et al. (2009)
Novel methods to deal with publication biases: secondary analysis of
antidepressant trials in the FDA trial registry database and related journal
publications. BMJ 339: b2981.
47. Jump RL, Pultz MJ, Donskey CJ (2007) Vegetative Clostridium difficile survives in
room air on moist surfaces and in gastric contents with reduced acidity: a
potential mechanism to explain the association between proton pump inhibitors
and C. difficile-associated diarrhea? Antimicrob Agents Chemother 51: 2883–
2887.
48. Wilson KH (1983) Efficacy of various bile salt preparations for stimulation of
Clostridium difficile spore germination. J Clin Microbiol 18: 1017–1019.
49. Theisen J, Nehra D, Citron D, Johannson J, Hagen J, et al. (2000) Suppression
of gastric acid secretion in patients with gastroesophageal reflux disease results in
gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg
4: 50–54.
50. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, et al. (1996) Bacterial
overgrowth during treatment with omeprazole compared with cimetidine: a
prospective randomized double blind study. Gut 39: 54–59.
51. Nerandzic MM, Pultz MJ, Donskey CJ (2009) Examination of Potential
Mechanisms To Explain the Association between Proton Pump Inhibitors and
Clostridium difficile Infection. Antimicrob Agents Chemother 53(10): 4133–4137.
52. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, et al. (2010) Clopidogrel
with or without omeprazole in coronary artery disease. N Engl J Med; 363:
1909–1917.
53. Boyce JM, Pittet D (2002) Healthcare Infection Control Practices Advisory
Committee; HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force.
MMWR Recomm Rep. 25;51(RR-16): 1–45.
Proton Pump Inhibitors and C. difficile Infection
PLOS ONE | www.plosone.org 12 December 2012 | Volume 7 | Issue 12 | e50836
